好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effect of Immunomodulatory Agents (IMAs) on Cortical Inflammatory Lesions (CLs) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): A 2-Year Longitudinal Comparison Study
MS and Related Diseases
(-)
001
Authors/Disclosures
Paolo Gallo, MD (Dompe' Biotec Italy) Dr. Gallo has nothing to disclose.
No disclosure on file
Francesca Rinaldi No disclosure on file
Ali Saber Tehrani, MD (Johns Hopkins University School of Medicine) Dr. Saber Tehrani has nothing to disclose.
Alice Favaretto No disclosure on file
No disclosure on file
David A. Shirilla, DO (Medical College Of Wisconsin Department Of Neurology) No disclosure on file
No disclosure on file
Luciano Rinaldi No disclosure on file
Massimiliano Calabrese (The Multiple Sclerosis Center, University Hospital of Verona) Massimiliano Calabrese has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis Pharma. Massimiliano Calabrese has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Serono. Massimiliano Calabrese has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Massimiliano Calabrese has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharma. Massimiliano Calabrese has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Massimiliano Calabrese has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Massimiliano Calabrese has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS Celgene. The institution of Massimiliano Calabrese has received research support from Roche.